BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study ...

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression ...

- Largest ever PSP clinical trial will evaluate the efficacy and safety of AMX0035 in adults with PSP compared to placebo “There is a pressing unmet need within the PSP community for new and effective ...

Progressive supranuclear palsy (PSP) is a rare, degenerative neurological condition. It usually starts in middle age and can cause symptoms similar to those of Parkinson’s disease. PSP can cause ...

ASN90, an O-GlcNAcase inhibitor, is a new chemical entity at clinical stage and a promising candidate for the treatment of PSP, a disorder with a high unmet medical need PSP is a rare neurological ...

CHICAGO -- Civil rights activist Rev. Jesse Jackson was hospitalized on Wednesday in Chicago, according to the Rainbow PUSH Coalition. Sources told our sister station WLS that Jackson was being ...

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial Ferrer, a B Corp-certified international pharmaceutical ...